Tom C. Thomas - 12 Aug 2024 Form 4 Insider Report for Vincerx Pharma, Inc. (VINC)

Footnote F1

On August 12, 2024, the stockholders of the Issuer approved the repricing of certain outstanding options to purchase common stock (the "Repriced Options"), with the new exercise price being the closing price of the Issuer's common stock on the Nasdaq Capital Market on August 12, 2024, rounded up to the nearest penny (the "Repricing"). There is no change to the number of shares underlying the Repriced Options or the vesting schedule or expiration dates of the Repriced Options. The Repricing was approved by the Board of Directors of the Issuer on June 26, 2024, based on the recommendation of the Compensation Committee of the Board of Directors.

Footnote F2

Option vests over three years, with 1/3 of the shares vesting on March 15, 2022, and 1/36th of the shares vesting monthly thereafter.

Footnote F3

Option vests over three years, with 1/3 of the shares vesting on December 23, 2022, and 1/36th of the shares vesting monthly thereafter.

Footnote F4

Option vests in twenty-four equal monthly installments starting from August 25, 2022.

Footnote F5

Option vests in twenty-four equal monthly installments starting from November 15, 2022.

Footnote F6

Option vests in twenty-four equal monthly installments starting from February 15, 2023.

Footnote F7

One-third (1/3) vests on March 7, 2025, with the remainder vesting in twenty-four equal monthly installments thereafter.